Top of page Skip navigation


Advisory Board




Khatereh Ahmadi, Head of Search and Valuation Europe, MSD

Dr. Khatereh Ahmadi has worked in the biotech/pharma industry for 18 years. She  currently leads the Search and Evaluation Business Development team in Europe and Middle East. Previous to MSD, she was a co-founder and CEO of reViral Ltd, leading a Series A round of $21M with Andera Partners and Orbimed.  She played a significant role in the spin out of Piramed Ltd, and subsequently became head of business development culminating in a significant deal with Genentech and acquisition of Piramed by Roche.  She has consulted for a number of EU and US companies in the oncology field. She obtained a PhD in biochemistry from King’s College London and held a post-doctoral position at the Ludwig Institute for Cancer Research in London working in the PI 3-kinase field. Dr. Ahmadi was awarded her MBA from Henley Management College.


Ashley Box, Director Business Development, Corporate Accounts, ThermoFisher

At Thermo Fisher Scientific, our mission affects everyone. That is, enabling our customers to make the world healthier, cleaner and safer. We do good work and everyone in my team contributes to this. Work with a purpose and work that matters. Our colleagues share a common set of values – integrity, intensity, innovation and involvement. Thermo Fisher Scientific is also committed to diversity and inclusion, which means creating a global environment that embraces and leverages the unique qualities and differences of our individual people.

We offer a competitive salary as well as a unique health and wellness-focused benefits package. And because we’re fully networked and doing amazing things in 50 countries, our people have the opportunity to work all over the world. If our people want to transfer, we try to make it happen.

Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.



Adrian Toutoungi, Partner, Taylor Wessing

Adrian is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.

Adrian has a wealth of experience in handling the IP aspects of University spin-outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat-panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.

Adrian publishes and speaks regularly on a variety of intellectual property issues.



Sarah Brereton, Chesterford Research Park 



Simon Chell, Executive Director Discovery Biology, AstraZeneca

Simon obtained his PhD at Bristol University studying the function of prostaglandins in colorectal tumorigenesis. Subsequent research into fundamental tumour biology at the Babraham Institute (Cambridge, UK) and the Friedrich Miescher Institute (Basel, Switzerland) led to Simon joining GSK in 2007 where he progressed to Senior Director in roles of increasing scientific responsibility – latterly, as Senior Scientific Director for GSK’s clinical research activities in sub-Saharan Africa.

Simon joined AstraZeneca in 2018 and currently leads UK & US Discovery Biology in Discovery Sciences, Biopharmaceutical R&D, where he is responsible for the delivery of therapeutic programs, technological innovations and new drug formats through a multidisciplinary department incorporating cell, molecular, biochemical and protein sciences. Simon is a Fellow of the Royal Society of Biology, an Advisory Board member of Apollo Therapeutics and a core member of ELRIG’s Science Strategy Committee. He has extensive experience in medicine creation and has led international functions and major public-private alliances across the fields of drug discovery, new drug formats and early clinical research.



Headline Sponsor











Media Supporters  



Event Supporters